Research pipeline
We combine the pioneering science of our collaborators with the recognised expertise of our core partners. Together, we are advancing a pipeline of potential first-in-class or best-in-class, child-focused therapeutic assets to address some of the most challenging indications in paediatric cancer.
CF-012
A potential first-in-class, ETV6 inhibitor for the treatment of Ewing sarcoma
In collaboration with:
University of Virginia
Dana-Farber Cancer Institute
Mass General Brigham
CF-033
A potential first-in-class allogeneic, PRAME-targeting iNKT cell therapy to treat advanced cancers in young patients
In collaboration with:
MiNK Therapeutics
University of Southampton
Work with us
Whether you’re a researcher with a therapeutic opportunity, a potential partner or an impact investor, we want to hear from you.
Research collaborations
Are you a research team, with a promising validated target in paediatric cancer? Our next deadline for expressions of interest is 4 September 2026.
Learn more
Partnering & investment opportunities
Are you an investor, or interested in partnering opportunities?
Explore partnering
News and events
We are creating a consortium united in the unwavering belief that we can challenge conventional approaches and accelerate translation of promising ideas into new therapies for children and young people affected by cancer.
Stay up to date on our latest news, events and research.
Inside C-Further’s operating model
In the article , we outline our framework and how our hybrid model creates long-term value and clinical impact.
What makes a strong C-Further collaboration proposal
In this article, we outline our evaluation framework and share what researchers and future partners from academia and industry should consider when preparing a collaboration proposal.
Interview with BiotechTV
BiotechTV’s Amy Brown speaks with C-Further JSC member Tony Hickson about transforming paediatric oncology through C-Further’s independent drug discovery model and how it differs from traditional biotech companies and grant funders.
Taking on the unique challenges of paediatric cancer
In this interview, Dr Marco Purbhoo, Head of Translational Medicine at MiNK Therapeutics, discusses how C‑Further is helping advance iNKT cell therapies and overcome key scientific and investment challenges in paediatric cancer.